Anti-proliferation

Ginsenoside F1
Catalog No: CFN99754

Ginsenoside has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, also as a novel anti-skin cancer drug with anti-proliferative and anti-migration features. Ginsenoside F1 has a potential for industrial cosmetic materials, it also has inhibitory effect of elastase and tyrosinase, it significantly reduces ultraviolet-B-induced cell death by maintaining constant levels of Bcl-2 and protects HaCaT cells from apoptosis caused by ultraviolet B irradiation.

(20S)-Protopanaxdiol
Catalog No: CFN99764

20(S)-Protopanaxdiol may be a potential new P-gp inhibitor for cancer treatment, it may induce the apoptosis via the down-regulation of Bcl-2 protein and the up-regulation of γH2Ax protein expression; it may inhibit the proliferation of Siha cells via the up-regulating the expressions of p53, p21, and autophagy related gene Beclin 1and MAP1-LC3, and down-regulating the expression of cyclin-E.

beta-Amyrin acetate
Catalog No: CFN99679

beta-Amyrin acetate has anti-inflammatory, antioxidant, and antidyslipidemic activities, it shows significant HMG-CoA-reductase and sEH inhibition. beta-Amyrin acetate also exhibits weak-moderate antiproliferative activity against the A2780 human ovarian cancer cell line.

Sesamolin
Catalog No: CFN99799

Sesaminol possesses antioxidative activity, can inhibit lipid peroxidation in rat liver and kidney. It also shows neuroprotection effect on hypoxic neuronal and PC12 cells through the suppression of ROS generation and MAPK activation.

Sennoside B
Catalog No: CFN99904

Sennoside B, a major purgative component, has a potential utility in the treatment of proliferative diseases, through inhibiting PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway. It and sennoside A also possess significant gastroprotective activities .